Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| 5:01 Acquisition Corp.FVAM · Entity 144989 | Director | October 16, 2020 | October 20, 2020 |
| Q32 Bio Inc.FIXX · Entity 5594 | Director | June 14, 2023 | June 15, 2023 |
| Vor Biopharma Inc.VOR · Entity 4763 | Director | May 22, 2025 | May 23, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
5:01 Acquisition Corp.
Report date October 16, 2020 · Filed October 20, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class B Common StockSEC Table II · derivative / convertible security | Direct | 30,000 |
Reported balance
After 2020-10-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-10-16 · Other · Acquired 30,000 · Balance 30,000 F1: The shares of Class B common stock are automatically convertible into the issuer's shares of Class A common stock at the time of the issuer's initial business combination on a one-for-one basis, subject to adjustment pursuant to certain anti-dilution rights, and have no expiration date. The shares of Class B common stock are subject to forfeiture under certain circumstances relating to the Reporting Person's service on the issuer's Board of Directors. F2: In connection with the issuer's initial public offering and the Reporting Person's appointment to the issuer's Board of Directors, 5:01 Acquisition LLC transferred 30,000 shares of Class B common stock to the Reporting Person. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares of Class B common stock are automatically convertible into the issuer's shares of Class A common stock at the time of the issuer's initial business combination on a one-for-one basis, subject to adjustment pursuant to certain anti-dilution rights, and have no expiration date. The shares of Class B common stock are subject to forfeiture under certain circumstances relating to the Reporting Person's service on the issuer's Board of Directors.
F2: In connection with the issuer's initial public offering and the Reporting Person's appointment to the issuer's Board of Directors, 5:01 Acquisition LLC transferred 30,000 shares of Class B common stock to the Reporting Person.
Q32 Bio Inc.
Report date June 14, 2023 · Filed June 15, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.03 · Expires 2033-06-14 | Direct | 23,000 |
Reported balance
After 2023-06-14 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-06-14 · Grant · Acquired 23,000 · Balance 23,000 F1: This option shall vest and become exercisable on the earlier of June 14, 2024 or the day immediately prior to the date of the Issuer's next annual meeting of stockholders occurring after the date of grant, in either case subject to the Reporting Person continuing in service on the Board as a Non-Employee Director through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: This option shall vest and become exercisable on the earlier of June 14, 2024 or the day immediately prior to the date of the Issuer's next annual meeting of stockholders occurring after the date of grant, in either case subject to the Reporting Person continuing in service on the Board as a Non-Employee Director through such vesting date.
Vor Biopharma Inc.
Report date May 22, 2025 · Filed May 23, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.19 · Expires 2035-05-21 | Direct | 30,000 |
Reported balance
After 2025-05-22 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-05-22 · Grant · Acquired 30,000 · Balance 30,000 F1: This option was granted to the Reporting Person pursuant to the Issuer's non-employee director compensation policy. The shares underlying the option vest and become exercisable on the earlier of (i) May 22, 2026 or (ii) the Issuer's next annual meeting of stockholders following the grant date, in each case, subject to the Reporting Person's continued service as a director through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: This option was granted to the Reporting Person pursuant to the Issuer's non-employee director compensation policy. The shares underlying the option vest and become exercisable on the earlier of (i) May 22, 2026 or (ii) the Issuer's next annual meeting of stockholders following the grant date, in each case, subject to the Reporting Person's continued service as a director through such date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Audentes Therapeutics, Inc.
Report date January 15, 2020 · Filed January 15, 2020
Section 16 reporting ended · disclosed 2020-01-15. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-01-15 transaction · row 1
1 source rowRow 1 · 2020-01-15 · Other · Disposed 261,458 · Balance 0 F1: On December 2, 2019, Audentes Therapeutics, Inc. (the "Company") entered into an Agreement and Plan of Merger (as it may be amended, supplemented or otherwise modified from time to time, the "Merger Agreement") with Astellas Pharma Inc. ("Astellas") and Asilomar Acquisition Corp., a wholly-owned subsidiary of Astellas ("Merger Sub"), pursuant to which Astellas acquired the Company by a tender offer for all shares of Company common stock (the "Offer") and a subsequent merger (the "Merger"), each of which became effective on January 15, 2020. Pursuant to the Merger Agreement, (i) Merger Sub purchased all shares of Company common stock that were validly tendered pursuant to the Offer for a cash payment equal to $60.00 per share (the "Offer Price") and (ii) all shares of Company common stock outstanding immediately prior to the effective time of the Merger (the "Effective Time"), were canceled and converted automatically into the right to receive the Offer Price. F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company restricted stock units, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company restricted stock unit was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such Company restricted stock unit immediately prior to such cancellation by (ii) an amount in cash equal to the Offer Price, without any interest. F3: Includes 47,776 shares of Company common stock issuable upon the settlement of restricted stock units. |
| Common StockSEC Table I · non-derivative | IndirectBy Matthew R. Patterson Revocable Trust | 0 |
Reported balance
After 2020-01-15 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2020-01-15 · Other · Disposed 171,814 · Balance 0 F1: On December 2, 2019, Audentes Therapeutics, Inc. (the "Company") entered into an Agreement and Plan of Merger (as it may be amended, supplemented or otherwise modified from time to time, the "Merger Agreement") with Astellas Pharma Inc. ("Astellas") and Asilomar Acquisition Corp., a wholly-owned subsidiary of Astellas ("Merger Sub"), pursuant to which Astellas acquired the Company by a tender offer for all shares of Company common stock (the "Offer") and a subsequent merger (the "Merger"), each of which became effective on January 15, 2020. Pursuant to the Merger Agreement, (i) Merger Sub purchased all shares of Company common stock that were validly tendered pursuant to the Offer for a cash payment equal to $60.00 per share (the "Offer Price") and (ii) all shares of Company common stock outstanding immediately prior to the effective time of the Merger (the "Effective Time"), were canceled and converted automatically into the right to receive the Offer Price. F4: The reporting person is the trustee of the Matthew R. Patterson Revocable Trust. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.50 · Expires 2025-12-18 | Direct | 0 |
Reported balance
After 2020-01-15 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-01-15 · Disposition to issuer · Disposed 143,569 · Balance 0 F5: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.26 · Expires 2027-01-25 | Direct | 0 |
Reported balance
After 2020-01-15 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2020-01-15 · Disposition to issuer · Disposed 188,334 · Balance 0 F5: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $27.39 · Expires 2027-11-16 | Direct | 0 |
Reported balance
After 2020-01-15 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2020-01-15 · Disposition to issuer · Disposed 225,000 · Balance 0 F5: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.74 · Expires 2029-02-06 | Direct | 0 |
Reported balance
After 2020-01-15 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2020-01-15 · Disposition to issuer · Disposed 177,450 · Balance 0 F5: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. |
Filing footnotes · ownership attribution and instrument terms
F1: On December 2, 2019, Audentes Therapeutics, Inc. (the "Company") entered into an Agreement and Plan of Merger (as it may be amended, supplemented or otherwise modified from time to time, the "Merger Agreement") with Astellas Pharma Inc. ("Astellas") and Asilomar Acquisition Corp., a wholly-owned subsidiary of Astellas ("Merger Sub"), pursuant to which Astellas acquired the Company by a tender offer for all shares of Company common stock (the "Offer") and a subsequent merger (the "Merger"), each of which became effective on January 15, 2020. Pursuant to the Merger Agreement, (i) Merger Sub purchased all shares of Company common stock that were validly tendered pursuant to the Offer for a cash payment equal to $60.00 per share (the "Offer Price") and (ii) all shares of Company common stock outstanding immediately prior to the effective time of the Merger (the "Effective Time"), were canceled and converted automatically into the right to receive the Offer Price.
F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company restricted stock units, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company restricted stock unit was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such Company restricted stock unit immediately prior to such cancellation by (ii) an amount in cash equal to the Offer Price, without any interest.
F3: Includes 47,776 shares of Company common stock issuable upon the settlement of restricted stock units.
F4: The reporting person is the trustee of the Matthew R. Patterson Revocable Trust.
F5: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 22, 2025 Filed May 23, 2025 21:45 UTC | Vor Biopharma Inc. VOR · Entity 4763 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $0.19 | $0.00 |
DisclosureSEC source: 0001415889-25-014527 · form4-05232025_050504.xml · derivative · entry 1 Patterson Matthew R · CIK 0001401018 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2035-05-21 F1 · derivative.exercise_date: This option was granted to the Reporting Person pursuant to the Issuer's non-employee director compensation policy. The shares underlying the option vest and become exercisable on the earlier of (i) May 22, 2026 or (ii) the Issuer's next annual meeting of stockholders following the grant date, in each case, subject to the Reporting Person's continued service as a director through such date. Read SEC document |
| May 23, 2024 Filed May 28, 2024 20:10 UTC | Vor Biopharma Inc. VOR · Entity 4763 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $1.61 | $0.00 |
DisclosureSEC source: 0001415889-24-014647 · form4-05282024_040511.xml · derivative · entry 1 Patterson Matthew R · CIK 0001401018 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2034-05-22 F1 · derivative.exercise_date: This option was granted to the Reporting Person pursuant to the Issuer's non-employee director compensation policy. The shares underlying the option vest and become exercisable on the earlier of (i) May 23, 2025 or (ii) the Issuer's next annual meeting of stockholders following the grant date, in each case, subject to the Reporting Person's continued service as a director through such date. Read SEC document |
| June 14, 2023 Filed Jun 15, 2023 18:33 UTC | Q32 Bio Inc. FIXX · Entity 5594 | GrantOption (Right to Buy) · Derivative | 23,000 | $0.00 Strike: $1.03 | $0.00 |
DisclosureSEC source: 0000950170-23-028411 · ownership.xml · derivative · entry 1 Patterson Matthew R · CIK 0001401018 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,000 Underlying: Common Stock · 23,000 shares Expires 2033-06-14 F1 · derivative.exercise_date: This option shall vest and become exercisable on the earlier of June 14, 2024 or the day immediately prior to the date of the Issuer's next annual meeting of stockholders occurring after the date of grant, in either case subject to the Reporting Person continuing in service on the Board as a Non-Employee Director through such vesting date. Read SEC document |
| May 26, 2023 Filed Jun 2, 2023 20:38 UTC | Vor Biopharma Inc. VOR · Entity 4763 | GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $4.79 | $0.00 |
DisclosureSEC source: 0001209191-23-033818 · doc4.xml · derivative · entry 1 Patterson Matthew R · CIK 0001401018 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2033-05-25 F1 · derivative.exercise_date: This option was granted to the Reporting Person pursuant to the Issuer's non-employee director compensation policy. The shares underlying the option vest and become exercisable on the earlier of (i) May 26, 2024 or (ii) the Issuer's next annual meeting of stockholders following the grant date, in each case, subject to the Reporting Person's continued service as a director through such date. Read SEC document |
| June 15, 2022 Filed Jun 17, 2022 16:06 UTC | Q32 Bio Inc. FIXX · Entity 5594 | GrantOption (Right to Buy) · Derivative | 18,000 | $0.00 Strike: $1.88 | $0.00 |
DisclosureSEC source: 0000899243-22-023069 · doc4.xml · derivative · entry 1 Patterson Matthew R · CIK 0001401018 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Stock · 18,000 shares Expires 2032-06-15 F1 · derivative.exercise_date: This option shall vest and become exercisable on the earlier of June 15, 2023 or the day immediately prior to the date of the Issuer's next annual meeting of stockholders occurring after the date of grant, in either case subject to the Reporting Person continuing in service on the Board as a Non-Employee Director through such vesting date. Read SEC document |
| June 14, 2022 Filed Jun 16, 2022 21:11 UTC | Vor Biopharma Inc. VOR · Entity 4763 | GrantStock Option (right to buy) · Derivative | 16,911 | $0.00 Strike: $4.26 | $0.00 |
DisclosureSEC source: 0001209191-22-037519 · doc4.xml · derivative · entry 1 Patterson Matthew R · CIK 0001401018 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,911 Underlying: Common Stock · 16,911 shares Expires 2032-06-13 F1 · derivative.exercise_date: This option was granted to the Reporting Person pursuant to the Issuer's non-employee director compensation policy. The shares underlying the option vest and become exercisable on the earlier of (i) June 14, 2023 or (ii) the Issuer's next annual meeting of stockholders following the grant date, in each case, subject to the Reporting Person's continued service as a director through such date. Read SEC document |
| June 17, 2021 Filed Jun 22, 2021 17:40 UTC | Q32 Bio Inc. FIXX · Entity 5594 | GrantOption (Right to Buy) · Derivative | 18,000 | $0.00 Strike: $7.26 | $0.00 |
DisclosureSEC source: 0000899243-21-025333 · doc4.xml · derivative · entry 1 Patterson Matthew R · CIK 0001401018 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Stock · 18,000 shares Expires 2031-06-17 F1 · derivative.exercise_date: This option shall vest and become exercisable on the earlier of June 17, 2022 or the day immediately prior to the date of the Issuer's next annual meeting of stockholders occurring after the date of grant, in either case subject to the Reporting Person continuing in service on the Board as a Non-Employee Director through such vesting date. Read SEC document |
| February 05, 2021 Filed Feb 9, 2021 22:16 UTC | Vor Biopharma Inc. VOR · Entity 4763 | GrantStock Option (right to buy) · Derivative | 16,900 | $0.00 Strike: $18.00 | $0.00 |
DisclosureSEC source: 0001209191-21-008891 · doc4.xml · derivative · entry 1 Patterson Matthew R · CIK 0001401018 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,900 Underlying: Common Stock · 16,900 shares Expires 2031-02-04 F1 · derivative.exercise_date: 1/36th of the shares underlying the option vest in equal monthly installments commencing on March 5, 2021, provided that the Reporting Person remains continuously engaged by the Issuer on each such vesting date. Read SEC document |
| October 16, 2020 Filed Oct 20, 2020 20:56 UTC | 5:01 Acquisition Corp. FVAM · Entity 144989 | OtherClass B Common Stock · Derivative | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-055443 · doc4.xml · derivative · entry 1 Patterson Matthew R · CIK 0001401018 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Class A Common Stock · 30,000 shares Expires not disclosed F1 · derivative.exercise_price: The shares of Class B common stock are automatically convertible into the issuer's shares of Class A common stock at the time of the issuer's initial business combination on a one-for-one basis, subject to adjustment pursuant to certain anti-dilution rights, and have no expiration date. The shares of Class B common stock are subject to forfeiture under certain circumstances relating to the Reporting Person's service on the issuer's Board of Directors. F2 · kind: In connection with the issuer's initial public offering and the Reporting Person's appointment to the issuer's Board of Directors, 5:01 Acquisition LLC transferred 30,000 shares of Class B common stock to the Reporting Person. F1 · derivative.exercise_date: The shares of Class B common stock are automatically convertible into the issuer's shares of Class A common stock at the time of the issuer's initial business combination on a one-for-one basis, subject to adjustment pursuant to certain anti-dilution rights, and have no expiration date. The shares of Class B common stock are subject to forfeiture under certain circumstances relating to the Reporting Person's service on the issuer's Board of Directors. F1 · derivative.expiration_date: The shares of Class B common stock are automatically convertible into the issuer's shares of Class A common stock at the time of the issuer's initial business combination on a one-for-one basis, subject to adjustment pursuant to certain anti-dilution rights, and have no expiration date. The shares of Class B common stock are subject to forfeiture under certain circumstances relating to the Reporting Person's service on the issuer's Board of Directors. Read SEC document |
| June 10, 2020 Filed Jun 12, 2020 17:27 UTC | Q32 Bio Inc. FIXX · Entity 5594 | GrantOption (Right to Buy) · Derivative | 18,000 | $0.00 Strike: $16.32 | $0.00 |
DisclosureSEC source: 0000899243-20-016390 · doc4.xml · derivative · entry 1 Patterson Matthew R · CIK 0001401018 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Stock · 18,000 shares Expires 2030-06-10 F1 · derivative.exercise_date: This option shall vest and become exercisable on the earlier of June 10, 2021 or the day immediately prior to the date of the next annual meeting of the Company's stockholders occurring after the date of grant, in either case subject to the Non-Employee Director continuing in service on the Board as a Non-Employee Director through such vesting date. Read SEC document |
| January 15, 2020 Filed Jan 15, 2020 13:35 UTC | Audentes Therapeutics, Inc. BOLD · Entity 122788 | Disposition to issuerStock Option (Right to Buy) · Derivative | 177,450 | Not disclosed Strike: $24.74 | Not disclosed |
DisclosureSEC source: 0001209191-20-003434 · doc4.xml · derivative · entry 6 Patterson Matthew R · CIK 0001401018 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 177,450 shares Expires 2029-02-06 F5 · price: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. F5 · derivative.exercise_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. Read SEC document |
| January 15, 2020 Filed Jan 15, 2020 13:35 UTC | Audentes Therapeutics, Inc. BOLD · Entity 122788 | Disposition to issuerStock Option (Right to Buy) · Derivative | 225,000 | Not disclosed Strike: $27.39 | Not disclosed |
DisclosureSEC source: 0001209191-20-003434 · doc4.xml · derivative · entry 5 Patterson Matthew R · CIK 0001401018 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 225,000 shares Expires 2027-11-16 F5 · price: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. F5 · derivative.exercise_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. Read SEC document |
| January 15, 2020 Filed Jan 15, 2020 13:35 UTC | Audentes Therapeutics, Inc. BOLD · Entity 122788 | Disposition to issuerStock Option (Right to Buy) · Derivative | 188,334 | Not disclosed Strike: $15.26 | Not disclosed |
DisclosureSEC source: 0001209191-20-003434 · doc4.xml · derivative · entry 4 Patterson Matthew R · CIK 0001401018 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 188,334 shares Expires 2027-01-25 F5 · price: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. F5 · derivative.exercise_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. Read SEC document |
| January 15, 2020 Filed Jan 15, 2020 13:35 UTC | Audentes Therapeutics, Inc. BOLD · Entity 122788 | Disposition to issuerStock Option (Right to Buy) · Derivative | 143,569 | Not disclosed Strike: $9.50 | Not disclosed |
DisclosureSEC source: 0001209191-20-003434 · doc4.xml · derivative · entry 3 Patterson Matthew R · CIK 0001401018 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 143,569 shares Expires 2025-12-18 F5 · price: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. F5 · derivative.exercise_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. Read SEC document |
| January 15, 2020 Filed Jan 15, 2020 13:35 UTC | Audentes Therapeutics, Inc. BOLD · Entity 122788 | OtherCommon Stock | 171,814 | $60.00 | $10,308,840.00 |
DisclosureSEC source: 0001209191-20-003434 · doc4.xml · nonDerivative · entry 2 Patterson Matthew R · CIK 0001401018 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Matthew R. Patterson Revocable Trust Disclosed balance after: 0 F1 · kind: On December 2, 2019, Audentes Therapeutics, Inc. (the "Company") entered into an Agreement and Plan of Merger (as it may be amended, supplemented or otherwise modified from time to time, the "Merger Agreement") with Astellas Pharma Inc. ("Astellas") and Asilomar Acquisition Corp., a wholly-owned subsidiary of Astellas ("Merger Sub"), pursuant to which Astellas acquired the Company by a tender offer for all shares of Company common stock (the "Offer") and a subsequent merger (the "Merger"), each of which became effective on January 15, 2020. Pursuant to the Merger Agreement, (i) Merger Sub purchased all shares of Company common stock that were validly tendered pursuant to the Offer for a cash payment equal to $60.00 per share (the "Offer Price") and (ii) all shares of Company common stock outstanding immediately prior to the effective time of the Merger (the "Effective Time"), were canceled and converted automatically into the right to receive the Offer Price. F4 · ownership.nature: The reporting person is the trustee of the Matthew R. Patterson Revocable Trust. Read SEC document |
| January 15, 2020 Filed Jan 15, 2020 13:35 UTC | Audentes Therapeutics, Inc. BOLD · Entity 122788 | OtherCommon Stock | 261,458 | $60.00 | $15,687,480.00 |
DisclosureSEC source: 0001209191-20-003434 · doc4.xml · nonDerivative · entry 1 Patterson Matthew R · CIK 0001401018 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: On December 2, 2019, Audentes Therapeutics, Inc. (the "Company") entered into an Agreement and Plan of Merger (as it may be amended, supplemented or otherwise modified from time to time, the "Merger Agreement") with Astellas Pharma Inc. ("Astellas") and Asilomar Acquisition Corp., a wholly-owned subsidiary of Astellas ("Merger Sub"), pursuant to which Astellas acquired the Company by a tender offer for all shares of Company common stock (the "Offer") and a subsequent merger (the "Merger"), each of which became effective on January 15, 2020. Pursuant to the Merger Agreement, (i) Merger Sub purchased all shares of Company common stock that were validly tendered pursuant to the Offer for a cash payment equal to $60.00 per share (the "Offer Price") and (ii) all shares of Company common stock outstanding immediately prior to the effective time of the Merger (the "Effective Time"), were canceled and converted automatically into the right to receive the Offer Price. F2 · kind: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company restricted stock units, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company restricted stock unit was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such Company restricted stock unit immediately prior to such cancellation by (ii) an amount in cash equal to the Offer Price, without any interest. F3 · shares: Includes 47,776 shares of Company common stock issuable upon the settlement of restricted stock units. Read SEC document |
| January 08, 2020 Filed Jan 10, 2020 18:18 UTC | Audentes Therapeutics, Inc. BOLD · Entity 122788 | Exercise / conversionStock Option (right to buy) · Derivative | 11,666 | $0.00 Strike: $15.26 | $0.00 |
DisclosureSEC source: 0001209191-20-003110 · doc4.xml · derivative · entry 10 Patterson Matthew R · CIK 0001401018 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 188,334 Underlying: Common Stock · 11,666 shares Expires 2027-01-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option vests as to 2.0833% of the total shares monthly, beginning February 25, 2017, with 100% of the total shares vested and exercisable on January 25, 2021, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
| January 08, 2020 Filed Jan 10, 2020 18:18 UTC | Audentes Therapeutics, Inc. BOLD · Entity 122788 | Exercise / conversionStock Option (right to buy) · Derivative | 11,824 | $0.00 Strike: $9.50 | $0.00 |
DisclosureSEC source: 0001209191-20-003110 · doc4.xml · derivative · entry 9 Patterson Matthew R · CIK 0001401018 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 143,569 Underlying: Common Stock · 11,824 shares Expires 2025-12-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option vested as to 6.25% of the total shares quarterly, beginning March 18, 2016, with 100% of the total shares vested and exercisable on December 18, 2019. Read SEC document |
| January 08, 2020 Filed Jan 10, 2020 18:18 UTC | Audentes Therapeutics, Inc. BOLD · Entity 122788 | Exercise / conversionStock Option (right to buy) · Derivative | 74,297 | $0.00 Strike: $2.19 | $0.00 |
DisclosureSEC source: 0001209191-20-003110 · doc4.xml · derivative · entry 8 Patterson Matthew R · CIK 0001401018 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 74,297 shares Expires 2025-02-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option vested as to 25% of the total shares on February 4, 2016, and then 6.25% of the total shares vest quarterly thereafter, with 100% of the total shares vested and exercisable on February 4, 2019. Read SEC document |
| January 08, 2020 Filed Jan 10, 2020 18:18 UTC | Audentes Therapeutics, Inc. BOLD · Entity 122788 | Exercise / conversionStock Option (right to buy) · Derivative | 64,751 | $0.00 Strike: $0.78 | $0.00 |
DisclosureSEC source: 0001209191-20-003110 · doc4.xml · derivative · entry 7 Patterson Matthew R · CIK 0001401018 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 64,751 shares Expires 2023-09-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option vested as to 25% of the total shares on January 1, 2014, and then 6.25% of the total shares quarterly thereafter, with 100% of the total shares vested and exercisable on January 1, 2017. Read SEC document |
| January 08, 2020 Filed Jan 10, 2020 18:18 UTC | Audentes Therapeutics, Inc. BOLD · Entity 122788 | Exercise / conversionCommon Stock | 11,666 | $15.26 | $178,023.16 |
DisclosureSEC source: 0001209191-20-003110 · doc4.xml · nonDerivative · entry 5 Patterson Matthew R · CIK 0001401018 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 261,458 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 08, 2020 Filed Jan 10, 2020 18:18 UTC | Audentes Therapeutics, Inc. BOLD · Entity 122788 | Exercise / conversionCommon Stock | 11,824 | $9.50 | $112,328.00 |
DisclosureSEC source: 0001209191-20-003110 · doc4.xml · nonDerivative · entry 4 Patterson Matthew R · CIK 0001401018 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 249,792 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 08, 2020 Filed Jan 10, 2020 18:18 UTC | Audentes Therapeutics, Inc. BOLD · Entity 122788 | Exercise / conversionCommon Stock | 74,297 | $2.19 | $162,710.43 |
DisclosureSEC source: 0001209191-20-003110 · doc4.xml · nonDerivative · entry 3 Patterson Matthew R · CIK 0001401018 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 237,968 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 08, 2020 Filed Jan 10, 2020 18:18 UTC | Audentes Therapeutics, Inc. BOLD · Entity 122788 | Exercise / conversionCommon Stock | 64,751 | $0.78 | $50,505.78 |
DisclosureSEC source: 0001209191-20-003110 · doc4.xml · nonDerivative · entry 2 Patterson Matthew R · CIK 0001401018 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,671 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 26, 2019 Filed Jan 10, 2020 18:18 UTC | Audentes Therapeutics, Inc. BOLD · Entity 122788 | GiftCommon Stock | 12,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-003110 · doc4.xml · nonDerivative · entry 1 Patterson Matthew R · CIK 0001401018 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,920 Read SEC document |
| December 05, 2019 Filed Dec 9, 2019 17:16 UTC | Audentes Therapeutics, Inc. BOLD · Entity 122788 | Tax withholdingCommon Stock | 1,974 | $59.21 | $116,880.54 |
DisclosureSEC source: 0001209191-19-059742 · doc4.xml · nonDerivative · entry 1 Patterson Matthew R · CIK 0001401018 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,420 F1 · kind: Shares relinquished by the Reporting Person and cancelled by the Issuer in exchange for the Issuer's agreement to pay federal and state tax withholding obligations of the Reporting Person resulting from the vesting of restricted stock units. The Reporting Person did not sell or otherwise dispose of the shares for any reason other than to cover required taxes. Read SEC document |
| November 08, 2019 Filed Nov 12, 2019 17:32 UTC | Audentes Therapeutics, Inc. BOLD · Entity 122788 | Exercise / conversionStock Option (right to buy) · Derivative | 14,426 | $0.00 Strike: $9.50 | $0.00 |
DisclosureSEC source: 0001209191-19-056113 · doc4.xml · derivative · entry 4 Patterson Matthew R · CIK 0001401018 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 155,393 Underlying: Common Stock · 14,426 shares Expires 2025-12-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F3 · derivative.exercise_date: The option vests as to 6.25% of the total shares quarterly, beginning March 18, 2016, with 100% of the total shares vested and exercisable on December 18, 2019, subject to the reporting person's provision of service to the issuer on each vesting date and to accelerated vesting upon the occurrence of certain events. Read SEC document |
| November 08, 2019 Filed Nov 12, 2019 17:32 UTC | Audentes Therapeutics, Inc. BOLD · Entity 122788 | SaleCommon Stock | 14,426 | $30.00 | $432,780.00 |
DisclosureSEC source: 0001209191-19-056113 · doc4.xml · nonDerivative · entry 2 Patterson Matthew R · CIK 0001401018 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,394 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| November 08, 2019 Filed Nov 12, 2019 17:32 UTC | Audentes Therapeutics, Inc. BOLD · Entity 122788 | Exercise / conversionCommon Stock | 14,426 | $9.50 | $137,047.00 |
DisclosureSEC source: 0001209191-19-056113 · doc4.xml · nonDerivative · entry 1 Patterson Matthew R · CIK 0001401018 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,820 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| September 05, 2019 Filed Sep 9, 2019 16:05 UTC | Audentes Therapeutics, Inc. BOLD · Entity 122788 | Tax withholdingCommon Stock | 1,974 | $31.02 | $61,233.48 |
DisclosureSEC source: 0001209191-19-048879 · doc4.xml · nonDerivative · entry 1 Patterson Matthew R · CIK 0001401018 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,394 F1 · kind: Shares relinquished by the Reporting Person and cancelled by the Issuer in exchange for the Issuer's agreement to pay federal and state tax withholding obligations of the Reporting Person resulting from the vesting of restricted stock units. The Reporting Person did not sell or otherwise dispose of the shares for any reason other than to cover required taxes. Read SEC document |
| August 12, 2019 Filed Aug 14, 2019 19:03 UTC | Audentes Therapeutics, Inc. BOLD · Entity 122788 | Exercise / conversionStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $9.50 | $0.00 |
DisclosureSEC source: 0001209191-19-046001 · doc4.xml · derivative · entry 5 Patterson Matthew R · CIK 0001401018 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 169,819 Underlying: Common Stock · 20,000 shares Expires 2025-12-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F5 · derivative.exercise_date: The option vests as to 6.25% of the total shares quarterly, beginning March 18, 2016, with 100% of the total shares vested and exercisable on December 18, 2019, subject to the reporting person's provision of service to the issuer on each vesting date and to accelerated vesting upon the occurrence of certain events. Read SEC document |
| August 12, 2019 Filed Aug 14, 2019 19:03 UTC | Audentes Therapeutics, Inc. BOLD · Entity 122788 | SaleCommon Stock | 1,000 | $34.53 | $34,525.00 |
DisclosureSEC source: 0001209191-19-046001 · doc4.xml · nonDerivative · entry 3 Patterson Matthew R · CIK 0001401018 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,368 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F3 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $34.35 and the highest price at which shares were sold was $34.98. Read SEC document |
| August 12, 2019 Filed Aug 14, 2019 19:03 UTC | Audentes Therapeutics, Inc. BOLD · Entity 122788 | SaleCommon Stock | 19,000 | $34.02 | $646,309.70 |
DisclosureSEC source: 0001209191-19-046001 · doc4.xml · nonDerivative · entry 2 Patterson Matthew R · CIK 0001401018 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,368 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $33.32 and the highest price at which shares were sold was $34.30. The reporting person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the ranges set forth in footnotes 2 and 3 to this Form 4. Read SEC document |
| August 12, 2019 Filed Aug 14, 2019 19:03 UTC | Audentes Therapeutics, Inc. BOLD · Entity 122788 | Exercise / conversionCommon Stock | 20,000 | $9.50 | $190,000.00 |
DisclosureSEC source: 0001209191-19-046001 · doc4.xml · nonDerivative · entry 1 Patterson Matthew R · CIK 0001401018 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,368 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| June 06, 2019 Filed Jun 10, 2019 17:10 UTC | Q32 Bio Inc. FIXX · Entity 5594 | GrantOption (Right to Buy) · Derivative | 15,580 | $0.00 Strike: $19.51 | $0.00 |
DisclosureSEC source: 0000899243-19-016224 · doc4.xml · derivative · entry 1 Patterson Matthew R · CIK 0001401018 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,580 Underlying: Common Stock · 15,580 shares Expires 2029-06-06 F1 · derivative.exercise_date: This option shall vest and become exercisable on the earlier of June 6, 2020 or the day immediately prior to the date of the next annual meeting of the Company's stockholders occurring after the date of grant, in either case subject to the Non-Employee Director continuing in service on the Board as a Non-Employee Director through each such vesting date. Read SEC document |
| June 05, 2019 Filed Jun 7, 2019 16:41 UTC | Audentes Therapeutics, Inc. BOLD · Entity 122788 | Tax withholdingCommon Stock | 3,332 | $37.31 | $124,316.92 |
DisclosureSEC source: 0001209191-19-035586 · doc4.xml · nonDerivative · entry 1 Patterson Matthew R · CIK 0001401018 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,368 F1 · kind: Shares relinquished by the Reporting Person and cancelled by the Issuer in exchange for the Issuer's agreement to pay federal and state tax withholding obligations of the Reporting Person resulting from the vesting of restricted stock units. The Reporting Person did not sell or otherwise dispose of the shares for any reason other than to cover required taxes. Read SEC document |
| February 25, 2019 Filed Feb 27, 2019 16:31 UTC | Audentes Therapeutics, Inc. BOLD · Entity 122788 | Exercise / conversionStock Option (right to buy) · Derivative | 4,000 | $0.00 Strike: $2.19 | $0.00 |
DisclosureSEC source: 0001209191-19-014072 · doc4.xml · derivative · entry 7 Patterson Matthew R · CIK 0001401018 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,297 Underlying: Common Stock · 4,000 shares Expires 2025-02-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F5 · derivative.exercise_date: The option vested as to 25% of the total shares on February 4, 2016, and then 6.25% of the total shares vest quarterly thereafter, with 100% of the total shares vested and exercisable on February 4, 2019, subject to the reporting person's provision of service to the issuer on each vesting date. F4 · balance_after: The exercise of 26,901 options on July 3, 2018 and 23,147 options on July 5, 2018, each having an exercise price of $2.19 per share, were previously reported on Form 4 filed on July 5, 2018 as having an exercise price of $0.78. This Form 4 reflects the correct number of options attributed to each grant and beneficially owned following the transactions reported in this Form 4. Read SEC document |
| February 25, 2019 Filed Feb 27, 2019 16:31 UTC | Audentes Therapeutics, Inc. BOLD · Entity 122788 | Exercise / conversionStock Option (right to buy) · Derivative | 17,000 | $0.00 Strike: $0.78 | $0.00 |
DisclosureSEC source: 0001209191-19-014072 · doc4.xml · derivative · entry 6 Patterson Matthew R · CIK 0001401018 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,751 Underlying: Common Stock · 17,000 shares Expires 2023-09-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F3 · derivative.exercise_date: The option vested as to 25% of the total shares on January 1, 2014, and then 6.25% of the total shares vest quarterly thereafter, with 100% of the total shares vested and exercisable on January 1, 2017, subject to the reporting person's provision of service to the issuer on each vesting date and to accelerated vesting in the event of the occurrence of certain events. F4 · balance_after: The exercise of 26,901 options on July 3, 2018 and 23,147 options on July 5, 2018, each having an exercise price of $2.19 per share, were previously reported on Form 4 filed on July 5, 2018 as having an exercise price of $0.78. This Form 4 reflects the correct number of options attributed to each grant and beneficially owned following the transactions reported in this Form 4. Read SEC document |
| February 25, 2019 Filed Feb 27, 2019 16:31 UTC | Audentes Therapeutics, Inc. BOLD · Entity 122788 | SaleCommon Stock | 4,000 | $30.00 | $120,000.00 |
DisclosureSEC source: 0001209191-19-014072 · doc4.xml · nonDerivative · entry 4 Patterson Matthew R · CIK 0001401018 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,700 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| February 25, 2019 Filed Feb 27, 2019 16:31 UTC | Audentes Therapeutics, Inc. BOLD · Entity 122788 | Exercise / conversionCommon Stock | 4,000 | $2.19 | $8,760.00 |
DisclosureSEC source: 0001209191-19-014072 · doc4.xml · nonDerivative · entry 3 Patterson Matthew R · CIK 0001401018 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,700 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| February 25, 2019 Filed Feb 27, 2019 16:31 UTC | Audentes Therapeutics, Inc. BOLD · Entity 122788 | SaleCommon Stock | 17,000 | $30.00 | $510,000.00 |
DisclosureSEC source: 0001209191-19-014072 · doc4.xml · nonDerivative · entry 2 Patterson Matthew R · CIK 0001401018 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,700 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| February 25, 2019 Filed Feb 27, 2019 16:31 UTC | Audentes Therapeutics, Inc. BOLD · Entity 122788 | Exercise / conversionCommon Stock | 17,000 | $0.78 | $13,260.00 |
DisclosureSEC source: 0001209191-19-014072 · doc4.xml · nonDerivative · entry 1 Patterson Matthew R · CIK 0001401018 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,700 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| February 06, 2019 Filed Feb 8, 2019 17:50 UTC | Audentes Therapeutics, Inc. BOLD · Entity 122788 | GrantStock Option (right to buy) · Derivative | 177,450 | $0.00 Strike: $24.74 | $0.00 |
DisclosureSEC source: 0001209191-19-008709 · doc4.xml · derivative · entry 3 Patterson Matthew R · CIK 0001401018 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 177,450 Underlying: Common Stock · 177,450 shares Expires 2029-02-06 F3 · derivative.exercise_date: The option vests as to 2.0833% of the total shares monthly, beginning February 1, 2019, with 100% of the total shares vested and exercisable on January 1, 2023, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
| February 06, 2019 Filed Feb 8, 2019 17:50 UTC | Audentes Therapeutics, Inc. BOLD · Entity 122788 | GrantCommon Stock | 63,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-008709 · doc4.xml · nonDerivative · entry 1 Patterson Matthew R · CIK 0001401018 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,700 F1 · shares: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the issuer's Common Stock upon settlement for no consideration. The RSUs will vest as to 2/16ths of the award on June 5, 2019, and then 1/16th of the RSUs will vest on each of September 5, December 5, March 5 and June 5 thereafter until the RSUs are fully vested, subject to the Reporting Person's provision of services to the issuer on each vesting date. Shares of the issuer's Common Stock will be delivered to the Reporting Person following vesting. Read SEC document |
| December 06, 2018 Filed Dec 10, 2018 16:39 UTC | Audentes Therapeutics, Inc. BOLD · Entity 122788 | Exercise / conversionStock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $0.78 | $0.00 |
DisclosureSEC source: 0001209191-18-061791 · doc4.xml · derivative · entry 3 Patterson Matthew R · CIK 0001401018 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,702 Underlying: Common Stock · 40,000 shares Expires 2023-09-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option vested as to 25% of the total shares on January 1, 2014, and then 6.25% of the total shares quarterly thereafter, with 100% of the total shares vested and exercisable on January 1, 2017. Read SEC document |
| December 06, 2018 Filed Dec 10, 2018 16:39 UTC | Audentes Therapeutics, Inc. BOLD · Entity 122788 | Exercise / conversionCommon Stock | 40,000 | $0.78 | $31,200.00 |
DisclosureSEC source: 0001209191-18-061791 · doc4.xml · nonDerivative · entry 1 Patterson Matthew R · CIK 0001401018 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 01, 2018 Filed Oct 2, 2018 19:04 UTC | Audentes Therapeutics, Inc. BOLD · Entity 122788 | Exercise / conversionStock Option (right to buy) · Derivative | 21,000 | $0.00 Strike: $0.78 | $0.00 |
DisclosureSEC source: 0001209191-18-053466 · doc4.xml · derivative · entry 10 Patterson Matthew R · CIK 0001401018 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,702 Underlying: Common Stock · 21,000 shares Expires 2023-09-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F7 · derivative.exercise_date: The option vested as to 25% of the total shares on January 1, 2014, and then 6.25% of the total shares vest quarterly thereafter, with 100% of the total shares vested and exercisable on January 1, 2017, subject to the reporting person's provision of service to the issuer on each vesting date and to accelerated vesting in the event of the occurrence of certain events. Read SEC document |
| October 01, 2018 Filed Oct 2, 2018 19:04 UTC | Audentes Therapeutics, Inc. BOLD · Entity 122788 | SaleCommon Stock | 8,078 | $37.70 | $304,572.91 |
DisclosureSEC source: 0001209191-18-053466 · doc4.xml · nonDerivative · entry 8 Patterson Matthew R · CIK 0001401018 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F5 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $37.41 and the highest price at which shares were sold was $37.875. Read SEC document |
| October 01, 2018 Filed Oct 2, 2018 19:04 UTC | Audentes Therapeutics, Inc. BOLD · Entity 122788 | Exercise / conversionCommon Stock | 8,078 | $0.78 | $6,300.84 |
DisclosureSEC source: 0001209191-18-053466 · doc4.xml · nonDerivative · entry 7 Patterson Matthew R · CIK 0001401018 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,078 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| October 01, 2018 Filed Oct 2, 2018 19:04 UTC | Audentes Therapeutics, Inc. BOLD · Entity 122788 | SaleCommon Stock | 5,448 | $38.58 | $210,162.05 |
DisclosureSEC source: 0001209191-18-053466 · doc4.xml · nonDerivative · entry 6 Patterson Matthew R · CIK 0001401018 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F4 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $38.22 and the highest price at which shares were sold was $38.81. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.